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OBJECTIVE
To compare effects of combinations of standard and intensive treatment of gly-
cemia and either blood pressure (BP) or lipids in the Action to Control Cardiovas-
cular Risk in Diabetes (ACCORD) trial.
RESEARCH DESIGN AND METHODS
ACCORD enrolled 10,251 type 2 diabetes patients aged 40–79 years at high risk for
cardiovascular disease (CVD) events. Participants were randomly assigned to he-
moglobin A1c goals of <6.0% (<42mmol/mol; intensive glycemia) or 7.0–7.9% (53–
63mmol/mol; standard glycemia) and then randomized a second time to either 1)
systolic BP goals of <120 mmHg (intensive BP) or <140 mmHg (standard BP) or 2)
simvastatin plus fenofibrate (intensive lipid) or simvastatin plus placebo (standard
lipid). Proportional hazards models were used to assess combinations of treat-
ment assignments on the composite primary (deaths due to CVD, nonfatal myo-
cardial infarction [MI], and nonfatal stroke) and secondary outcomes.
RESULTS
In the BP trial, risk of the primary outcome was lower in the groups intensively
treated for glycemia (hazard ratio [HR] 0.67; 95% CI 0.50–0.91), BP (HR 0.74; 95% CI
0.55–1.00), or both (HR 0.71; 95% CI 0.52–0.96) comparedwith combined standard
BP and glycemia treatment. For secondary outcomes,MIwas significantly reduced
by intensive glycemia treatment and stroke by intensive BP treatment; most other
HRs were neutral or favored intensive treatment groups. In the lipid trial, the
general pattern of results showed no evidence of benefit of intensive regimens
(whether single or combined) compared with combined standard lipid and glyce-
mia treatment. Themortality HRwas 1.33 (95% CI 1.02–1.74) in the standard lipid/
intensive glycemia group compared with the standard lipid/standard glycemia
group.
CONCLUSIONS
In the ACCORD BP trial, compared with combined standard treatment, intensive
BP or intensive glycemia treatment alone improvedmajor CVD outcomes, without
additional benefit from combining the two. In the ACCORD lipid trial, neither
intensive lipid nor glycemia treatment produced an overall benefit, but intensive
glycemia treatment increased mortality.
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Cardiovascular disease (CVD) is themost
common cause of death and disability in
patients with type 2 diabetes mellitus,
and dysglycemia, high blood pressure
(BP), and dyslipidemia mediate much
of this increased CVD risk (1). Treatment
trials focused on single risk factor mod-
ification have shown that lowering
glucose, BP, and lipids substantially re-
duces CVD events and deaths in patients
with type 2 diabetes (2–4). The Steno-2
Study showed a major reduction in CVD
events and mortality with multifacto-
rial intensive treatment (5,6). When
the Action to Control Cardiovascular
Risk in Diabetes (ACCORD) trial was de-
signed, the study questions focused on
the separate effectiveness of three dis-
tinct single-factor interventions target-
ing near-normal levels of hemoglobin
A1c (HbA1c) versus standard levels,
near-normal levels of systolic BP versus
standard levels, and combined lipid-
lowering therapy with a fibrate and an
hydroxymethylglutaryl CoA reductase
inhibitor (statin) versus monotherapy
with a statin (7–10).
Assessment of the effectiveness of
combined versus single intensive inter-
ventions was not the primary objective
of ACCORD. However, the factorial
study design permits these planned
analyses, and their potential relevance
has only increased given the somewhat
unexpected pattern of findings of the
ACCORD trials (11–14). None of the
three intensive intervention strategies
had a significant beneficial main effect
on the primary outcome, a composite of
cardiovascular death, nonfatal myocar-
dial infarction (MI), and nonfatal stroke
(major CVD). All-cause mortality and
CVD mortality were increased by the in-
tensive glycemia intervention and not
altered by intensive treatment of BP or
an intensive lipid treatment strategy. At
the same time, the risk of nonfatal MI
was reduced by intensive treatment of
glycemia, and risk of fatal and nonfatal
stroke was reduced by intensive treat-
ment of BP.
In previously published analyses, a
modest interaction was observed for
the outcome of total mortality between
the intensive glycemia and BP interven-
tions (P = 0.03); the group that received
both intensive interventions had the
highestmortality, while the groups receiv-
ing either or both standard interventions
had lower mortality (Supplemental Fig. 4
in 11). No significant interaction was
found for the primary composite out-
come of major CVD, and no interactions
were found for either outcome between
the glycemia and lipid interventions.
However, intensive glycemia assignment
was associated with a nonsignificant
26–33% elevated risk of mortality regard-
less of lipid treatment assignment.
The purpose of this article is to ex-
plore these treatment combinations in
more depth by examining outcomes
separately in the lipid and BP trials and
by examining outcomes separately for
the intensive and standard glycemia
participants within those trials. In the
BP trial, we compare standard treat-
ment of glycemia and BP with both sin-
gle and joint intensive treatment of
glycemia and BP. In the lipid trial, we
conduct a parallel comparison of stan-
dard glycemia and lipid treatment with
both single and joint intensive interven-
tions. This analytic strategy was not pre-
specified but was developed before the
data presented here were analyzed. The
goal was to determine whether macro-
vascular, microvascular, or mortality
outcomes differed in any of the three
intensively treated groups in each trial
compared with the group that received
standard treatment.
RESEARCH DESIGN AND METHODS
The rationale, design, methods, and ma-
jor outcomes of the ACCORD trial have
been published previously (7–10,12–
15). In brief, ACCORD was a double
two-by-two factorial trial designed to
test whether, compared with standard
treatment, more intensive control of
glycemia, BP, or dyslipidemia might re-
duce risk of cardiovascular death, non-
fatal MI, and nonfatal stroke (major
CVD). Men and women with type 2 di-
abetes aged 40 to 79 years and with
HbA1c $7.5% ($58 mmol/mol) and
who had prior evidence of CVD or mul-
tiple cardiovascular risk factors were re-
cruited in 77 clinics across the U.S. and
Canada from January 2001 to October
2005. All participants were required to
qualify for the glycemia trial and at least
one of the nested trials (BP or lipid). In
the glycemia trial, participants were ran-
domized to HbA1c goals of ,6.0% (,42
mmol/mol; intensive) or 7.0–7.9% (53–
63 mmol/mol; standard). In the BP trial,
participants were randomized to sys-
tolic BP goals of,120mmHg (intensive)
or ,140 mmHg (standard). In the lip-
id trial, participants were randomized
in a masked fashion to combined ther-
apy with fenofibrate plus simvastatin
(intensive) or placebo plus simvastatin
(standard).
The glycemia trial was terminated
early due to an observed 22% greater
relative risk of death in the intensively
treated participants (12). Participants
were informed of the decision to termi-
nate the glucose-lowering comparison
on 5 February 2008, after a mean treat-
ment period of 3.7 years. From this tran-
sition date onward, the intensity of
glycemia interventions in the intensive
group was reduced to that of the stan-
dard group and HbA1c targets were
changed from ,6% (,42 mmol/mol) to
between 7 and 7.9% (53–63 mmol/mol).
As participants had also been allocated
to either the BP trial or the lipid trial,
they continued to be followed per pro-
tocol either every 2 or 4 months until
the originally planned trial end (June
2009). Thus clinical outcomes contin-
ued to be collected and blindly ad-
judicated centrally for an additional
17 months.
The effects of the glycemia interven-
tion during a mean of 3.5 years that pro-
vided the basis for the Data Safety
Monitoring Board (DSMB) recommen-
dation were previously reported (12)
and were updated to reflect the effect
of the intervention the additional 0.2
years (i.e., until 5 February 2008) when
intensive glycemia participants were in-
formed of the change in glycemia man-
agement (11). This article reports the
effects of the glycemia, BP, and lipid in-
terventions over of a mean of 3.7 years
of follow-up using an intention-to-treat
analysis.
The primary end point for ACCORD
was major CVD events, defined as the
composite of deaths due to CVD, non-
fatal MI, and nonfatal stroke. This article
will also report the following secondary
outcomes: total mortality, CVD deaths,
any MI, any stroke, an expanded macro-
vascular outcome (including major fatal
and nonfatal CVD events in the primary
outcome, revascularizations, and heart
failure hospitalizations), and the two
protocol-specified microvascular dis-
ease composite outcomes (15). The first
microvascular disease composite com-
bined advanced kidney and eye disease
and was intended to approximate the
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primary microvascular outcome of the
UK Prospective Diabetes Study (16);
the second added peripheral neuropa-
thy to that outcome.
Variables are described using themean
(SD) or median (interquartile range) for
continuous measures and proportions
for categorical variables. The use of med-
ications from various classes is described
based on the last visit for each participant
prior to 5 February 2008, when the inten-
sive glycemia intervention was stopped.
Mean HbA1c, BP, and lipid levels at the
last visit prior to stopping the glycemia
intervention are reported for each of
the four combination of treatment as-
signments in both the BP and lipid trials.
Differences in event rates between ran-
domized groups were tested using pro-
portional hazards regression analysis
adjusting for the design factors of clini-
cal center network, baseline history of
CVD, and BP trial or lipid trial assign-
ment. All analyses were performed us-
ing SAS version 9. In keeping with other
ACCORD secondary analyses, adjust-
ment for multiple comparisons was
not performed.
ACCORD was sponsored by the Na-
tional Heart, Lung, and Blood Institute
(NHLBI) with support from other Na-
tional Institutes of Health (NIH) insti-
tutes, and the protocol was reviewed,
approved in advance, and monitored
by an NHLBI DSMB and by ethics com-
mittees at each center. All participants
provided written informed consent. All
authors vouch for the accuracy and
completeness of the reported data.
RESULTS
The allocation of participants and
the completeness of follow-up in the
ACCORD trial have been reported pre-
viously (12–14). Characteristics of the
10,251 participants by trial are shown
in Table 1. Overall, participants included
an ethnically diverse group of middle-
aged and older men and women with
poorly controlled type 2 diabetes of
long duration. Mean BMI at randomiza-
tion was 32.2 kg/m2, and 35.2% had one
or more major cardiovascular events
prior to randomization. Although all par-
ticipants qualified for the glycemia trial,
the inclusion and exclusion criteria for
the BP and lipid trials differed by design
(8–10). Participants in the BP trial and
the lipid trial differed on several charac-
teristics: BP trial participants were more
likely to be black, to be female, and to
have higher BP levels. They also had
lower triglyceride levels and higher HDL
and LDL cholesterol concentrations.
Lipid trial participants were more likely
to have smoked and to have had previ-
ous CVD events, had lower BP, had
higher triglyceride levels, and had lower
HDL and LDL cholesterol concentrations.
The treatments prescribed to partici-
pants are shown by treatment group in
Table 2. All glucose-lowering medica-
tions were used more commonly and
at higher mean doses in the intensive
glycemia group, but the largest differ-
ences were for insulin use (any and bo-
lus) and thiazolidinediones. Similarly,
all major BP-lowering medication clas-
ses were used more commonly in the
intensive BP group, with the largest dif-
ference for diuretics. BP medications
were used similarly across lipid trial
groups. Aspirin use was similar across
groups. Statins were used similarly in
nearly in all lipid trial participants by de-
sign and were also used similarly but at
lower levels in BP trial participants.
In the BP trial, mean HbA1c levels at
the last visit were similar in standard
and intensive glycemia participants re-
gardless of treatment assignment to
standard or intensive BP intervention
(Table 3). Parallel analyses in the lipid
trial participants showed similar find-
ings. Mean BP levels were 1–2 mmHg
lower in intensive glycemia group par-
ticipants than in standard glycemia
group participants in the lipid trial and
in the standard BP groups of the BP trial.
LDL cholesterol levels were similar
across all treatment assignments in
both trials. HDL cholesterol levels were
highest relative to the other treatment
assignments in the standard BP/inten-
sive glycemia group in the BP trial and
in the intensive lipid/intensive glycemia
group in the lipid trial. Triglyceride levels
were lowest in the intensive glycemia
and intensive lipid treatment groups.
The hazard ratio (HR), corresponding
95% CI, and 5-year event rates for the
study outcomes are shown in Fig. 1 for
the BP trial and in Fig. 2 for the lipid trial.
In both figures, the least intensively
treated group (standard BP/standard gly-
cemia group or standard lipid/standard
glycemia group) serves as the reference
group. In the BP trial, most of the point
estimates of the HRs were neutral or
favored the more intensively treated








Age (years) 62.2 (6.8) 62.3 (6.8) 62.2 (6.8)
Women 47.7 30.7 38.5
Ethnicity
White 60.5 68.4 64.8
Black 24.1 15.1 19.3
Hispanic 7.0 7.4 7.2
Other 15.8 17.2 16.6
Median duration of diabetes (years) 10 (10) 9 (10) 10 (10)
Previous CVD event 33.7 36.5 35.2
Smoking status
Current smoker 13.2 14.6 14.0
Former smoker 41.9 46.2 44.2
BMI (kg/m2) 32.1 (5.6) 32.3 (5.4) 32.2 (5.5)
Systolic BP (mmHg) 139.2 (15.8) 133.9 (17.8) 136.4 (17.1)
Diastolic BP (mmHg) 76.0 (10.4) 74.0 (10.8) 74.9 (10.7)
Median HbA1c (%) 8.3 (1.1) 8.3 (1.0) 8.3 (1.1)
Median HbA1c (mmol/mol) 67.0 (12.0) 67.0 (10.9) 67.0 (12.0)
Total cholesterol (mg/dL) 192.8 (44.8) 175.2 (37.3) 183.3 (41.8)
LDL cholesterol (mg/dL) 110.0 (36.7) 100.6 (30.7) 104.9 (33.9)
HDL cholesterol in women (mg/dL) 51.3 (13.8) 41.4 (7.8) 47.0 (12.6)
HDL cholesterol in men (mg/dL) 41.7 (11.8) 36.6 (7.3) 38.6 (9.6)
Median triglyceride (mg/dL) 147 (128) 162 (116) 155 (122)
Serum creatinine (mg/dL) 0.9 (0.2) 0.9 (0.2) 0.9 (0.2)
Data are percentage, mean (SD), or median (interquartile range).
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groups. All threemore intensively treated
groups in the BP trial experienced sig-
nificantly lower rates of the primary out-
come, major CVD, with HRs ranging
from 0.67 to 0.74 when compared with
the standard BP/standard glycemia
group. Both of the more intensively
treated glycemia groups experienced
lower rates of MI, while both of the
more intensively treated BP groups expe-
rienced lower rates of stroke when com-
pared with the standard BP/standard
glycemia group. The expanded macro-
vascular end point favored all of the
more intensively treated groups, but
only the standard BP/intensive glycemia
group had a significantly lower event
rate than the standard BP/standard gly-
cemia reference group (HR 0.83; 95% CI
0.70–0.98). There was no statistical evi-
dence of benefit or harm regarding total
mortality, CVD mortality, or microvascu-
lar disease for any of the more inten-
sively treated groups. Of particular
note, while the intensive BP/intensive
glycemia group showed evidence of
benefit regarding major CVD, any MI,
and any stroke compared with the stan-
dard BP/standard glycemia group, the
benefits were not different from those
observed for the single-factor intensive
regimens.
In the lipid trial, the general pattern of
results showed no evidence of benefit of
intensive regimens (whether single fac-
tor or combined) relative to the stan-
dard lipid/standard glycemia group.
Mortality was 33% higher in the stan-
dard lipid/intensive glycemia group
than in the standard lipid/standard gly-
cemia group (HR 1.33; 95% CI 1.02–
1.74), and total and CVD mortality
were nonsignificantly higher in the
intensive glycemia group relative to
the standard lipid/standard glycemia
group regardless of lipid treatment
assignment.
CONCLUSIONS
Although none of the individual inten-
sive interventions reduced the ACCORD
trial primary outcome of major CVD,
these current planned analyses of the
effects of single and combined intensive
intervention regimens on major macro-
vascular outcomes in the ACCORD tri-
al provide a somewhat different view
of the results than those published to
date. First, compared with the stan-
dard BP/standard glycemia group, the
intensive BP/intensive glycemia, inten-
sive BP/standard glycemia, and stan-
dard BP/intensive glycemia groups all
showed benefit for reducing the risk of
major CVD in the BP trial. However, the
intensive BP/intensive glycemia group
showed no evidence of incremental
benefit compared with either single in-
tensive intervention. Second, in the BP
trial, MI was significantly reduced in the
intensive glycemia treatment groups
and stroke in the intensive BP treatment
groups. Third, compared with the stan-
dard lipid/standard glycemia group,
there was no evidence of benefit of ei-
ther the intensive lipid or intensive gly-
cemia intervention in the lipid trial, and
there was increased mortality in the
standard lipid/intensive glycemia group.
None of the intensive interventions, sin-
gly or in combination, affected the risk
of advanced microvascular outcomes,
which is consistent with previously pub-
lished findings (15,17).
These results raise several questions.
Why did the intensive BP and intensive
glycemia interventions fail to show ad-
ditive effects in the BP trial? For major
CVD, MI, stroke, and macrovascular dis-
ease, one or both of the single-factor
intensive regimens was at least as effec-
tive in reducing risk as was the com-
bined intensive regimen. Might this
finding provide evidence of a “floor ef-
fect,” i.e., a diminishing ability of inten-
sive treatments to lower risk further
Table 2—Prevalence of medication use by participants in various treatment groups of the ACCORD BP and lipid trial at the last
visit prior to stopping the intensive glycemia intervention
Medication class
BP trial Lipid trial

























Insulin (any) 618 (52.5) 884 (74.1) 639 (54.0) 853 (72.4) 700 (51.1) 1,016 (73.5) 758 (54.6) 979 (71.3)
Insulin bolus 275 (23.3) 517 (43.3) 273 (23.1) 505 (42.9) 284 (20.7) 593 (42.9) 337 (24.3) 627 (45.6)
Metformin 836 (71.0) 912 (76.5) 787 (66.5) 819 (69.5) 1,014 (74.0) 1,106 (80.0) 896 (64.5) 1,010 (73.5)
Secretagogue 608 (51.6) 713 (59.8) 623 (52.6) 724 (61.5) 799 (58.3) 871 (63.0) 786 (56.6) 861 (62.7)
Thiazolidinedione 341 (29.0) 654 (54.8) 328 (27.7) 592 (50.3) 405 (29.6) 779 (56.3) 417 (30.0) 760 (55.3)
Acarbose 48 (4.1) 147 (12.3) 44 (3.7) 139 (11.8) 40 (2.9) 189 (13.7) 51 (3.7) 190 (13.8)
Other glucose-lowering
medication 48 (4.1) 144 (12.1) 49 (4.1) 167 (14.2) 43 (3.1) 193 (14.0) 58 (4.2) 186 (13.5)
BP-lowering agent (any) 1,092 (92.7) 1,085 (91.0) 1,159 (97.9) 1,159 (98.4) 1,137 (83.0) 1,108 (80.1) 1,126 (81.1) 1,089 (79.3)
Diuretic 670 (56.9) 646 (54.2) 946 (79.9) 939 (79.7) 635 (46.4) 606 (43.8) 581 (41.8) 601 (43.7)
ACE inhibitor 625 (53.1) 611 (51.2) 726 (61.3) 676 (57.4) 697 (50.9) 670 (48.5) 683 (49.2) 647 (47.1)
Angiotensin receptor
blocker 365 (31.0) 340 (28.5) 491 (41.5) 454 (38.5) 298 (21.8) 280 (20.3) 260 (18.7) 276 (20.1)
Beta-blocker 434 (36.8) 412 (34.5) 574 (48.5) 542 (46.0) 532 (38.8) 506 (36.6) 548 (39.5) 475 (34.6)
Calcium channel blocker 202 (17.2) 180 (15.1) 386 (32.6) 321 (27.3) 301 (22.0) 301 (21.8) 318 (22.9) 291 (21.2)
Aspirin 747 (63.4) 721 (60.4) 698 (59.0) 690 (58.6) 850 (62.0) 866 (62.6) 860 (61.9) 856 (62.3)
Statin 725 (61.5) 723 (60.6) 719 (60.7) 723 (61.4) 1,192 (87.0) 1,208 (87.4) 1,207 (86.9) 1,165 (84.8)
Data are n (%).
1724 Combined CVD Risk Factor Management in ACCORD Diabetes Care Volume 37, June 2014
when one risk factor is reduced to near-
normal levels and the other risk factor is
reasonably well controlled? While this
possibility is speculative, the results of
the AIM HIGH (Atherothrombosis Inter-
vention inMetabolic SyndromeWith Low
HDL/High Triglycerides: Impact on Global
Health Outcomes) trial provide additional
evidence of some pertinence (18). In this
trial, in the setting of very well-controlled
cholesterol (using a moderate-dose sta-
tin), further lowering of LDL cholesterol
by the addition of niacin had no further
impact on risk of CVD, despite achieving
better HDL cholesterol and triglyceride
levels. The results of AIM HIGH contrast
with results of the Coronary Drug Project,
conducted in the prestatin era, which
demonstrated a cardioprotective effect
of niacin alone (19). If the reason for
that discrepancy is the standard use of
statins in AIM HIGH, then it seems possi-
ble that the substantial use of aspirin in
over 60% in both trials, and statins in over
60% in the ACCORD BP trial and over
85% in the ACCORD lipid trial, may
have reduced the ability of the intensive
interventions in ACCORD to further re-
duce CVD outcomes. Similarly, in stud-
ies designed to show safety of newer
glucose-lowering drugs, the new agent
is typically added to existing therapy in
patients receiving high-quality back-
ground therapy, many of whom also
have well-controlled glycemia. In the
context of the ACCORD results, perhaps
it is not surprising that such studies
have failed to show CVD benefit (20,21).
Why did the intensive glycemia inter-
vention appear to reduce the risk for
major CVD in the BP trial but not in the
lipid trial, and why did it appear to in-
crease mortality in the lipid trial but not
in the BP trial? Unlike a 3 3 3 design,
which would have required a much
larger sample size, the double 2 3 2
factorial study design did not permit a
comparison of various combinations of
all three interventions. Given differen-
ces in eligibility criteria and underlying
Table 3—HbA1c, BP, and lipids at the last visit prior to stopping the intensive glycemia intervention
Measure
BP trial Lipid trial

















Median HbA1c (%) 7.5 (1.1) 6.5 (1.1) 7.5 (1.2) 6.4 (1.2) 7.6 (1.2) 6.3 (1.1) 7.6 (1.2) 6.4 (1.1)
Median HbA1c
(mmol/mol) 58.0 (12.0) 48.0 (12.0) 58.0 (13.1) 46.0 (13.1) 60.0 (13.1) 45.0 (12.0) 60.0 (13.1) 46.0 (12.0)
Mean systolic BP
(mmHg) 134.7 (15.6) 133.3 (14.9) 120.2 (14.6) 120.5 (15.0) 130.5 (18.8) 128.8 (18.0) 129.3 (17.6) 128.6 (18.1)
Mean diastolic BP
(mmHg) 70.9 (10.5) 69.7 (10.7) 64.4 (10.2) 64.3 (9.9) 69.4 (11.1) 67.8 (10.9) 68.2 (10.7) 67.4 (11.1)
Mean LDL cholesterol
(mg/dL) 100.4 (39.5) 100.2 (38.8) 102.8 (41.4) 102.1 (41.2) 82.9 (27.4) 84.4 (26.9) 83.6 (26.7) 84.0 (27.6)
Mean HDL cholesterol
(mg/dL) 46.8 (14.9) 47.6 (14.4) 46.1 (14.4) 45.6 (13.6) 39.4 (8.9) 40.4 (9.7) 39.9 (10.0) 40.8 (11.4)
Median triglycerides
(mg/dL) 141.0 (120.0) 127.0 (99.0) 142.5 (119.0) 140.0 (119.0) 155.0 (117.0) 137.0 (99.0) 130.5 (90.0) 117.0 (86.0)
Data are mean (SD) or median (interquartile range).
Figure 1—Five-year event rates, HR, and corresponding 95% CI for comparisons of the three
more intensively treated groups to the standard BP-lowering/standard glucose-lowering treat-
ment group in the ACCORD BP trial. P values are for pairwise comparisons of more intensively
treated groups with the standard/standard group. BP, blood pressure; Gly, glycemia; std, stan-
dard; int, intensive; macrovasc, macrovascular end point; microvasc, microvascular end point.
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risk for CVD events for the participants
in the two trials, a simple comparison of
the event rates for the intensive glyce-
mia groups in the BP and lipid trials
could be misleading. Although the char-
acteristics of the participants in the two
trials differed somewhat, there was sub-
stantial overlap, and previous subgroup
analyses from ACCORD do not point to
any measured participant characteris-
tics or drug treatments that might ex-
plain the difference in the estimated
effect of the intensive glycemia inter-
vention on CVD between the trials.
There may have been more subclinical
CVD in the lipid trial, an unmeasured
characteristic that could have influ-
enced the risk of subsequent major
CVD. In previous subgroup analyses, in-
tensive glycemia group participants
with a CVD event before randomization
had a higher risk of major CVD during
the trial compared with participants
with no prior history of CVD (12). It is
also possible that the greater use of
statins in the lipid trial reduced the abil-
ity to detect the glycemia treatment ef-
fect observed in the BP trial, although
this seems unlikely given that event rates
in the reference group in the lipid trial
were similar or higher than in the BP trial.
Finally, given the lack of an overall effect
of the glycemia intervention in ACCORD,
chance cannot be excluded as the basis
for the difference between the trials.
In the Steno-2 Study, an intensive
multifactorial intervention that included
targeting glycemia, BP, lipids, and aspi-
rin use reduced the risk of CVD by;50%
in patients with diabetes over 7.8 years
of follow-up (6). How can the results of
Steno-2 and ACCORD be reconciled?
First, it is important to note that the in-
tensive levels of risk factor control
achieved in Steno-2 approximate the
standard levels of control achieved in
ACCORD. It is possible that ACCORD
was operating on a much flatter part of
the risk curve. That is, it is possible that
the benefits of going from fair risk factor
control (Steno-2 standard group) to
moderate risk factor control (Steno-2 in-
tensive group) exceed the benefits of
going from moderate risk factor control
(ACCORD standard groups) to intensive
risk factor control (ACCORD intensive
groups). Second, it is not possible to
determine from Steno-2 whether the
entire multifactor intervention was
needed, which interventions provided
most of the benefit, or whether an ef-
fect almost as great might have been
achieved with a less comprehensive ap-
proach. The intensive intervention in
Steno-2 included many lifestyle inter-
ventions that were recommended as
background therapy for both random-
ized groups in ACCORD. It is notable
that the Steno-2 Study achieved positive
outcomes with a mean HbA1c of 7.8%
(62 mmol/mol) in the intensive group,
while mean systolic BP was ;132
mmHg and mean LDL was ;80 mg/dL.
Given the two-group design of the trial,
it is impossible to disentangle the indi-
vidual treatment effects in Steno-2.
Several factors constrain the interpre-
tation of the data presented here. First,
although these analyses were planned
in the ACCORD study, they are second-
ary analyses and should mainly be
viewed as exploratory. Second, because
we analyzed results across individual
cells of a factorial design with shorter
follow-up than originally intended, our
power to detect meaningful differences
and interactions between groups was re-
duced. On the other hand, the observed
P values must be considered in light of
the 48 reported comparisons. By chance
alone, two or three significant results
would be expected at P = 0.05, fewer
than the eight we observed. Third,
the observed results may apply only to
ACCORD-like patients; extrapolation to
other patients, especially to younger or
healthier patients with shorter duration
of diabetes, must await the results of ad-
ditional trials. The recently completed
Secondary Prevention of Small Subcorti-
cal Strokes (SPS3) trial provides some ad-
ditional evidence of stroke reduction by
intensive BP control in patients with re-
cent lacunar stroke. SPS3 compared a sys-
tolic BP target of 130–149 mmHg with a
target ,130 mmHg and achieved a sepa-
ration of 11 mmHg between the groups.
Therewas a nonsignificantly lower risk of
the primary outcome of recurrent stroke
in the group treated to the lower BP
Figure 2—Five-year event rates, HR, and corresponding 95% CI for comparisons of the three
more intensively treated groups to the fibrate placebo/standard glucose-lowering treatment
group in the ACCORD lipid trial. P values are for pairwise comparisons of more intensively
treated groups with the standard (placebo)/standard group. Gly, glycemia; Lip, lipid; std, stan-
dard; int, intensive; macrovasc, macrovascular end point; microvasc, microvascular end point.
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target (HR 0.81; 95% CI 0.64–1.03; P =
0.08) and a significant reduction in hemor-
rhagic stroke (HR 0.37; 95% CI 0.15–0.95;
P = 0.03) (22). In addition, the ongoing
Systolic Blood Pressure Intervention Trial
(SPRINT) in is testing a similar intensive BP
intervention in a nondiabetic popula-
tion (https://www.sprinttrial.org/public/
dspHome.cfm; accessed 20 June 2013.)
We now summarize the results of the
current secondary analyses, place them
in the context of the previously pub-
lished primary analyses, and discuss
implications for clinical practice. In dia-
betes patients resembling those in the
ACCORD lipid trial, addition of feno-
fibrate to a statin, intensive glycemia
control, or the combination did not pre-
vent major CVD or other CVD outcomes
better than standard glycemia control
with statin use. These results are consis-
tent with the primary analyses, except
that the previously observed increase in
mortality associated with intensive gly-
cemia control seems limited to this sub-
set of ACCORD participants. These
secondary analyses newly suggest that
in diabetes patients resembling those in
the ACCORD BP trial, either intensive BP
or glycemia control reduces major CVD
compared with combined standard
treatment, but the combination was no
better than the individual intensive inter-
ventions. The current results are consistent
with thepreviouslypublishedprimary anal-
yses in that intensive glycemia control
reduces MI while intensive BP control re-
duces stroke, although the glycemia find-
ings are limited to the subset of ACCORD
participants in the BP trial. In this subset,
there was no evidence of increased mor-
tality with either intensive intervention.
Both the intensive BP control and
intensive glycemia control strategies re-
quire more medications and more visits
than the standard control strategies.
Participants in both intensive treatment
groups also experienced significantly
higher rates of adverse effects that
were attributed to treatment. These in-
cluded more weight gain and serious hy-
poglycemia in the intensive glycemia
group and more hypotension, syncope,
bradycardia/arrhythmia, and hyperkale-
mia in the intensive BP group (12–14).
Nevertheless, it may be easier and safer
to achieve near-normal systolic BP and
to use statins than to achieve near-
normal levels of HbA1c with themultidrug
glucose-lowering regimens that were
used in ACCORD. These and previous
ACCORD analyses suggest that there is a
potential for increased mortality with in-
tensive glycemia treatment in a subset of
patients who are difficult to identify.
There is no corresponding evidence of
an increased mortality risk with intensive
BP treatment. A recent meta-analysis of
treatment trials in people with type 2 di-
abetes who had systolic BP#135 mmHg
in the intensive BP group and #140
mmHg in the standard BP group found a
10% (95% CI 2–17%) reduction in total
mortality (23). Several trials, including
the ACCORDBP trial, with intensive group
systolic BP ,120 were included in the
meta-analysis, and none found increased
mortality in the ,120 mmHg group.
In patients with longstanding type 2 di-
abetes andhighCVD risk resembling those
in the ACCORD lipid trial, these analyses
do not support adding fenofibrate to a
statin, intensive glycemia control, or the
combination. In patients similar to those
enrolled in the ACCORD BP trial, these
analyses provide limited support for in-
tensive BP control and even more limited
support for intensive glycemia control to
reduce the risk of major CVD. Any kind of
treatment intensification requires more
visits and medications and exposure to
adverse effects, but intensifying BP con-
trol in patients with diabetes may be less
risky than intensifying glycemia control,
which reduced MI but was associated
with increasedmortality in some patients.
Thus intensive BP control may be reason-
able in certain motivated patients who
have been educated about the added
treatment burden, cost, and risk of side
effects and want to further lower their
risk of stroke beyond what can be
achieved through standard care. There
may be other patients forwhom intensive
glycemia control may be beneficial to fur-
ther reduce their risk ofMI. Froma clinical
point of view, the results presented here
confirm the great importance of tailoring
treatment goals and treatment intensity
to specific subgroups of patients. The
choice of whether to pursue either inten-
sive BP control or intensive glycemia con-
trol using multidrug regimens will require
shared decisionmaking between the phy-
sician and patient about their individual
medical profiles, goals, and preferences.
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